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Data were retrospectively collected at several points in time from medical records
and hospital information systems on baseline characteristics, treatments, dosages,
treatment response, survival, adverse events and resource use. All patients entered
the registry at time of diagnosis. RESULTS: Our registries contained information of
615 mRCC and 3093 haematological cancer patients (non-Hodgkin, multiple my-
eloma, and chronic lymphocytic leukaemia). They provided important information
about how patients, including those regularly excluded from clinical trials, are
treated in daily practice. However, important data, including prognostic informa-
tion, was commonly missing (e.g. 40-55% missing performance status). Further-
more, patients treated with the drug of interest were not comparable to patients
not treated with this drug. Moreover, only small numbers of patients received the
drug of interest (mRCC: N34; non-Hodgkin: N35), and many patients received
different drugs in various combinations and treatment sequences in haematologi-
cal cancers. This, in combination with the inability to fully correct for confounding,
complicates the estimation of a real-world incremental cost-effectiveness
estimate. CONCLUSIONS: Our registries provided important information to physi-
cians and policymakers to enhance quality of care and facilitate evidence-based
decision making. Although population-based registries include high numbers of
patients, it remains a challenge to obtain sufficient numbers of similarly treated
and comparable patients. Therefore, it is inevitable to use data synthesis in com-
bination with comprehensive modelling techniques to obtain valid real-world in-
cremental cost-effectiveness estimates.
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OBJECTIVES: Smoking is a leading cause of early dead and morbidity in the West-
ern World. The purpose of this study is to evaluate how tobacco sales and tobacco
survey data correlates with lung cancer incidence in the Danish population. It is
estimated that up to 86% of lung cancer cases in developed countries are smoking
related. METHODS: Lung cancer incidence data from 1943-2009 are from Nordcan
(www.ancr.nu). Sale of tobacco (cigarettes/inhabitant) 1920-2010. Smoking habit
surveys from 1953-2010, annually from 1969. Lung cancer incidence is age stan-
dardized to the Nordic population (ASR(N)), and is in rate per 100.000/year. Corre-
lations are analyzed with Spearman’s rho with SPSS18. RESULTS: The strongest
correlation (spearman’s rho  0.92, p0.0001) is found between sale of cigarettes
and incidence of lung cancer with a lag time of 24 years. The correlation between
lung cancer and the proportion of the population that smokes is well correlated for
men (0.8, p0.0001, lag time20 years). Female smokers and lung cancer are with
a lag time of 5-26 years negatively correlated, but correlates positively when the lag
time is more than 27 years, the best correlation being 0.732 (p0.039, lag time35
years).CONCLUSIONS: The correlation between lung cancer incidence and the sale
of cigarettes is better than for the proportion of smokers. This might be because
sale gives a better estimation of the overall exposure in a form of population “pack
years”. The negative correlation between the proportion of female smokers and
lung cancer, and the change to a positive correlation when a longer lag time is
applied can be either a true finding that might be explained by longer development
time in females. Or it could be a result of changes in the accuracy of the proportion,
or a result of changes in the age pattern.
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OBJECTIVES: The new value-based system of pricing branded medicines in the UK
is nearing the launch phase with unresolved concerns towards developing the new
pricing framework and executing the system. This study identifies the strategies
proposed by stakeholders for the successful implementation of VBP and also de-
termines the ‘relative importance weights’ of additional value-elements i.e., bur-
den of illness, innovation and societal benefit introduced in the new pricing
framework. METHODS: In-depth qualitative and survey-based interviews were
conducted with 23 experts identified in pharmaceutical industry, NHS and SMC
advisory committees, NHS hospitals and pharmacies. RESULTS: Pharmaceutical
industry should adapt to a new model that brings innovation in R&D, addresses
unmet need and demonstrates the value of a new drug by gathering real-world
evidence. Government or payers should proactively publish guidelines before the
launch or propose a transitional arrangement for pharma in 2014. The local uptake
of medicines should be encouraged by introducing national settlement schemes
and incentivizing the local commissioning groups. It is possible that government
and pharmaceutical industry will direct more efforts towards improving the inter-
action between prescribers and patients for gathering real-world evidence. The
results also indicated that clinical-effectiveness and cost-effectiveness will remain
the prime metric in valuation process, however, burden of illness and innovation
may carry more weight than other value-elements. Societal benefit still needs to be
broadly defined; and innovation should ultimately translate into improved clinical
efficacy. The study also highlights the impact of VBP on each stakeholder group and
across disease areas with a focus on primary care and oncology. CONCLUSIONS:
The stakeholders still lack the clear understanding of VBP and believe that ulti-
mately it might be restructuring of the existing system given the limited time left
for its implementation. Even though the new pricing framework includes addi-
tional criteria, pricing decisions are anticipated to be made on a case-by-case basis
eventually.
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OBJECTIVES: Patient access or risk sharing schemes (PASs) have recently been
increasingly used, enabling easier and swifter access to new treatments, especially
in oncology. However, PASs frequently do not deliver the required results. The aim
was to create a conceptual framework that allows the selection of the most appro-
priate PAS in different countries. METHODS: A targeted literature review has been
conducted to identify PAS specific literature in oncology. Based on the review and
the evaluation of the currently implemented PASs in the EU, a three-level concep-
tual framework has been constructed. It is based on a list of criteria identified as
country-specific prerequisite for the different types of PASs. Each criterion can be
achieved by different tools/techniques, each with a list of basic requirements. PASs
for each country can be evaluated using simple scoring system for each criterion.
The proposed framework has been validated by EU industry experts and payer’s
representatives and tested for the UK and Hungary.RESULTS:The literature review
identified large number of abstracts and studies; however only 14 met the inclusion
criteria. These were mainly from the UK and US. The criteria evaluated authorities’
roles and responsibilities, transparency throughout the negotiation process and
implementation phase for all stakeholders, presence of trust and cooperation
among payers and manufacturers, availability of budget, clear patient pathways,
data availability, administration capacity and appropriate incentives for the stake-
holders. The test results were in accordance with the expert’s views and empha-
sized the insights from recent experiences and case studies. CONCLUSIONS: The
conceptual framework offers a good starting point for the evaluation of the poten-
tial success of the different PASs in oncology in a given country. Future steps could
include extension of therapeutic area, incorporation of relative weights for the
criteria and extending the countries used for validation.
PCN158
ADHERENCE TO HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2)
TESTING & ADJUVANT TRASTUZUMAB TREATMENT GUIDELINES IN A
CANADIAN PROVINCE
Ferrusi IL1, Trudeau M2, Earle CC3, Leighl N4, Pullenayegum E1, Khong H5, Hoch J6,
Marshall D7
1McMaster University, Hamilton, ON, Canada, 2Sunnybrook Health Science Centre, Toronto, ON,
Canada, 3Cancer Care Ontario / Institute for Cancer Research, Toronto, ON, Canada, 4Princess
Margaret Hospital, Toronto, ON, Canada, 5Alberta Bone & Joint Health Institute, Calgary, AB,
Canada, 6Cancer Care Ontario, Toronto, ON, Canada, 7University of Calgary, Calgary, AB,
Canada
OBJECTIVES: We evaluated the use of confirmatory HER2 fluorescence in situ hy-
bridisation (FISH) and predictors of trastuzumab use in early-stage breast cancer
(ESBC) in the province of Ontario. The adherence of practice patterns to provincial
adjuvant trastuzumab treatment guidelines and national HER2 testing consensus
guidelines was assessed. METHODS: A retrospective cohort of ESBC patients diag-
nosed in 2006-7 was identified in the Ontario Cancer Registry (OCR). HER2 test type,
sequence, result(s) and status, tumour grade and hormone receptor status were
determined from centrally-held (OCR) pathology reports. Trastuzumab treatment
was determined from provincial cancer agency records. Demographic, local health
integration network (LHIN), surgical, prior radiological and anthracycline treat-
ment and comorbidity data were determined from administrative data sources.
Logistic models were used to estimate adjusted odds ratios for factors associated
with guideline adherence. RESULTS: The first HER2 test result was the largest
predictor of confirmatory testing, with HER2 equivocal tumours being significantly
more likely to be retested vs. positive (OR 116 [79, 169]). Confirmatory testing varied
by LHIN but not by age. Patients diagnosed with stage III disease had significantly
higher odds of receiving a confirmatory test vs. stage I (OR 1.5 [1.1, 2.1]). HER2 status
was the largest predictor of trastuzumab use in the cohort, with HER2 equivocal,
negative or unknown status patients significantly less likely to receive treatment
than positive. Patients with advanced age at diagnosis (70y) had lower odds of
trastuzumab treatment compared to younger patients (OR 0.5 [0.3, 0.7]). Increasing
tumour grade was associated with higher odds of treatment. Treatment varied
significantly by LHIN. CONCLUSIONS: Despite limitations in centrally-reported tu-
mour pathology, we demonstrate that the use of confirmatory FISH testing in On-
tario was largely consistent with Canadian guidelines. Trastuzumab use in the
cohort was consistent with provincial guidelines on HER2 status in many patients,
though practice varies across LHINs.
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OBJECTIVES: To determine treatment patterns among individuals treated for un-
resectable stage III and IV melanoma in the Brazilian public and private health care
system. METHODS: A retrospective chart review was conducted in patients with
unresectable stage III and IV melanoma or relapsed between January 01 2008 and
December 31 2009. Patients had to have at least two months follow up in 12 private
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